A new probiotic treatment for Type 1 Diabetes
A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes
['FUNDING_SBIR_2'] · RISE THERAPEUTICS, LLC · NIH-10653229
This study is testing a new probiotic treatment using a friendly bacteria called Lactococcus lactis to help people with Type 1 Diabetes manage their blood sugar and improve their health by focusing on the gut.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RISE THERAPEUTICS, LLC (nih funded) |
| Locations | 1 site (Rockville, UNITED STATES) |
| Trial ID | NIH-10653229 on ClinicalTrials.gov |
What this research studies
This research aims to develop a novel probiotic therapy using Lactococcus lactis to treat Type 1 Diabetes (T1D). The approach focuses on harnessing the gut microbiome's immune regulatory mechanisms to improve glycemic control and overall patient well-being. By targeting the gut, this therapy seeks to address the underlying immunological issues associated with T1D, potentially reducing the risk of complications such as kidney failure and stroke. Patients will be monitored for changes in their immune response and overall health as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Type 1 Diabetes who are seeking alternative treatment options beyond insulin therapy.
Not a fit: Patients who do not have Type 1 Diabetes or those who are not responsive to probiotic treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, non-invasive treatment option for managing Type 1 Diabetes and improving patients' quality of life.
How similar studies have performed: Previous studies have shown that fecal microbiome therapy can halt the progression of new onset Type 1 Diabetes, indicating potential success for this novel probiotic approach.
Where this research is happening
Rockville, UNITED STATES
- RISE THERAPEUTICS, LLC — Rockville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FURLAN FREGUIA, CHRISTIAN — RISE THERAPEUTICS, LLC
- Study coordinator: FURLAN FREGUIA, CHRISTIAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.